The University of Chicago Header Logo

Connection

Stephen Hanauer to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Treatment Outcome.
Stephen Hanauer
Connection Strength
2.982
Treatment Outcome
  1. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
    View in: PubMed
    Score: 0.096
  2. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
    View in: PubMed
    Score: 0.093
  3. EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way? Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1377-1378.
    View in: PubMed
    Score: 0.093
  4. Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease. Immunotherapy. 2022 12; 14(17):1353-1359.
    View in: PubMed
    Score: 0.087
  5. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.
    View in: PubMed
    Score: 0.079
  6. Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2020 11 19; 26(12):1808-1818.
    View in: PubMed
    Score: 0.075
  7. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32.
    View in: PubMed
    Score: 0.071
  8. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147.
    View in: PubMed
    Score: 0.065
  9. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
    View in: PubMed
    Score: 0.065
  10. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.056
  11. Oral or Topical 5-ASA in Ulcerative Colitis. Dig Dis. 2016; 34(1-2):122-4.
    View in: PubMed
    Score: 0.054
  12. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
    View in: PubMed
    Score: 0.049
  13. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014 Jan; 39(2):163-75.
    View in: PubMed
    Score: 0.046
  14. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63.
    View in: PubMed
    Score: 0.045
  15. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94.
    View in: PubMed
    Score: 0.042
  16. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5.
    View in: PubMed
    Score: 0.042
  17. Complications of peristomal recurrence of Crohn's disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012 May-Jun; 39(3):297-301.
    View in: PubMed
    Score: 0.042
  18. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
    View in: PubMed
    Score: 0.042
  19. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98.
    View in: PubMed
    Score: 0.038
  20. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93.
    View in: PubMed
    Score: 0.036
  21. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3.
    View in: PubMed
    Score: 0.035
  22. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.034
  23. Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59.
    View in: PubMed
    Score: 0.031
  24. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68.
    View in: PubMed
    Score: 0.031
  25. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34.
    View in: PubMed
    Score: 0.031
  26. Parallel universes. Nat Clin Pract Gastroenterol Hepatol. 2007 Aug; 4(8):411.
    View in: PubMed
    Score: 0.030
  27. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007 May; 23(5):1033-43.
    View in: PubMed
    Score: 0.029
  28. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802.
    View in: PubMed
    Score: 0.029
  29. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):209-14.
    View in: PubMed
    Score: 0.029
  30. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2.
    View in: PubMed
    Score: 0.029
  31. Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22.
    View in: PubMed
    Score: 0.029
  32. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86.
    View in: PubMed
    Score: 0.028
  33. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40.
    View in: PubMed
    Score: 0.028
  34. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9.
    View in: PubMed
    Score: 0.028
  35. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464.
    View in: PubMed
    Score: 0.027
  36. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
    View in: PubMed
    Score: 0.027
  37. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85.
    View in: PubMed
    Score: 0.027
  38. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493.
    View in: PubMed
    Score: 0.027
  39. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12.
    View in: PubMed
    Score: 0.026
  40. Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6.
    View in: PubMed
    Score: 0.026
  41. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71.
    View in: PubMed
    Score: 0.025
  42. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.
    View in: PubMed
    Score: 0.025
  43. Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis. J Crohns Colitis. 2024 Nov 04; 18(11):1863-1869.
    View in: PubMed
    Score: 0.025
  44. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:60-5.
    View in: PubMed
    Score: 0.025
  45. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
    View in: PubMed
    Score: 0.024
  46. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.
    View in: PubMed
    Score: 0.024
  47. Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719.
    View in: PubMed
    Score: 0.024
  48. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88.
    View in: PubMed
    Score: 0.024
  49. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. J Crohns Colitis. 2024 Apr 23; 18(4):493-505.
    View in: PubMed
    Score: 0.024
  50. Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease. Dig Dis Sci. 2024 Jun; 69(6):2044-2054.
    View in: PubMed
    Score: 0.024
  51. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13.
    View in: PubMed
    Score: 0.023
  52. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
    View in: PubMed
    Score: 0.023
  53. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
    View in: PubMed
    Score: 0.023
  54. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2.
    View in: PubMed
    Score: 0.023
  55. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296.
    View in: PubMed
    Score: 0.022
  56. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64.
    View in: PubMed
    Score: 0.022
  57. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7.
    View in: PubMed
    Score: 0.022
  58. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
    View in: PubMed
    Score: 0.022
  59. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
    View in: PubMed
    Score: 0.021
  60. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
    View in: PubMed
    Score: 0.021
  61. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
    View in: PubMed
    Score: 0.021
  62. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890.
    View in: PubMed
    Score: 0.020
  63. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan; 16(1):87-99.
    View in: PubMed
    Score: 0.020
  64. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4.
    View in: PubMed
    Score: 0.019
  65. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
    View in: PubMed
    Score: 0.018
  66. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92.
    View in: PubMed
    Score: 0.017
  67. No butts about it: put the fire out by lighting up. Inflamm Bowel Dis. 1998 Nov; 4(4):326; discussion 327.
    View in: PubMed
    Score: 0.016
  68. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
    View in: PubMed
    Score: 0.016
  69. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology. 1998 Sep; 115(3):525-32.
    View in: PubMed
    Score: 0.016
  70. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77.
    View in: PubMed
    Score: 0.016
  71. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.016
  72. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.016
  73. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998 May; 4(2):79-83.
    View in: PubMed
    Score: 0.016
  74. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
    View in: PubMed
    Score: 0.016
  75. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
    View in: PubMed
    Score: 0.016
  76. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671.
    View in: PubMed
    Score: 0.015
  77. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997 Sep; 92(9):1424-8.
    View in: PubMed
    Score: 0.015
  78. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
    View in: PubMed
    Score: 0.015
  79. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578.
    View in: PubMed
    Score: 0.014
  80. The management of ulcerative colitis. Annu Rev Med. 1995; 46:497-505.
    View in: PubMed
    Score: 0.013
  81. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis. 2014 May; 20(5):872-81.
    View in: PubMed
    Score: 0.012
  82. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7.
    View in: PubMed
    Score: 0.012
  83. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.011
  84. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):754-60.
    View in: PubMed
    Score: 0.011
  85. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.011
  86. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.011
  87. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7.
    View in: PubMed
    Score: 0.010
  88. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
    View in: PubMed
    Score: 0.010
  89. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9.
    View in: PubMed
    Score: 0.010
  90. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56.
    View in: PubMed
    Score: 0.010
  91. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201.
    View in: PubMed
    Score: 0.010
  92. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17.
    View in: PubMed
    Score: 0.010
  93. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11.
    View in: PubMed
    Score: 0.010
  94. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
    View in: PubMed
    Score: 0.010
  95. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.010
  96. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51.
    View in: PubMed
    Score: 0.010
  97. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
    View in: PubMed
    Score: 0.010
  98. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7.
    View in: PubMed
    Score: 0.009
  99. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93.
    View in: PubMed
    Score: 0.009
  100. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1.
    View in: PubMed
    Score: 0.009
  101. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.
    View in: PubMed
    Score: 0.009
  102. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9.
    View in: PubMed
    Score: 0.009
  103. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.009
  104. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
    View in: PubMed
    Score: 0.009
  105. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36.
    View in: PubMed
    Score: 0.008
  106. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22.
    View in: PubMed
    Score: 0.008
  107. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31.
    View in: PubMed
    Score: 0.008
  108. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9.
    View in: PubMed
    Score: 0.008
  109. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar; 134(3):688-95.
    View in: PubMed
    Score: 0.008
  110. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5.
    View in: PubMed
    Score: 0.008
  111. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8.
    View in: PubMed
    Score: 0.008
  112. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
    View in: PubMed
    Score: 0.007
  113. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9.
    View in: PubMed
    Score: 0.007
  114. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86.
    View in: PubMed
    Score: 0.007
  115. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.
    View in: PubMed
    Score: 0.007
  116. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25.
    View in: PubMed
    Score: 0.007
  117. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8.
    View in: PubMed
    Score: 0.007
  118. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7.
    View in: PubMed
    Score: 0.007
  119. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
    View in: PubMed
    Score: 0.006
  120. First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6.
    View in: PubMed
    Score: 0.005
  121. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8.
    View in: PubMed
    Score: 0.005
  122. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1461-72.
    View in: PubMed
    Score: 0.005
  123. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1473-82.
    View in: PubMed
    Score: 0.005
  124. Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg. 2000 Sep; 232(3):401-8.
    View in: PubMed
    Score: 0.005
  125. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 06; 340(18):1398-405.
    View in: PubMed
    Score: 0.004
  126. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35.
    View in: PubMed
    Score: 0.004
  127. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells. Exp Hematol. 1996 Jun; 24(7):823-8.
    View in: PubMed
    Score: 0.003
  128. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 1996 Feb; 17(2):157-62.
    View in: PubMed
    Score: 0.003
  129. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.